Autoimmunerkrankungen

  • Gerd Horneff
  • Volker Wahn
Chapter

Zusammenfassung

Autoimmunität zählt zu den interessantesten Phänomenen, und das Wissen auf diesem Gebiet einschließlich der Therapieoptionen hat in den letzten Jahren erhebliche Fortschritte gemacht. Zu den grundlegenden immunologischen Phänomenen wird auf die spezielle Literatur verwiesen. Aufgrund der Komplexität der Befunde muss von einer multifaktoriellen Genese ausgegangen werden, bei der neben genetischen Faktoren, zu denen HLA-Moleküle zählen, Hormone, Umwelteinflüsse, Chemikalien und Infektionen von Bedeutung sind. Charakterisiert werden können Autoimmunerkrankungen oftmals durch humorale oder zelluläre Immunreaktionen gegen körpereigene Gewebe. Zu ihrer Manifestation müssen verschiedene Faktoren zusammentreffen. Systemische Autoimmunerkrankungen sind oft schwer und lebensbedrohlich.

This is a preview of subscription content, log in to check access.

Literatur

  1. Alarcon-Segovia D, Villarreal M (1987) Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed Connective Tissue Disease and Anti-Nuclear Natobodies. Amsterdam, Niederlanden, Excerpta Medica 33–40Google Scholar
  2. Appel GB, Contreras G, Dooley MA; Aspreva Lupus Management Study Group. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103–1112PubMedCentralPubMedCrossRefGoogle Scholar
  3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403–407PubMedCrossRefGoogle Scholar
  4. Bootsma H, Spronk P, Derksen R et al. (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345: 1595–1599. Erratum in: Lancet 346: 516Google Scholar
  5. Brueckner CS, Becker MO, Kroencke T et al. (2010) Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 69: 1475–1478PubMedCentralPubMedCrossRefGoogle Scholar
  6. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58: 556–562PubMedCrossRefGoogle Scholar
  7. Dajani As, Taubert KA, Takahashi M et al. (1994) Guidelines for the long term management of patients with Kaewasaki disease. Circulation 89: 916–922PubMedCrossRefGoogle Scholar
  8. Dalakas MC, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRefGoogle Scholar
  9. Erkan D, Harrison MJ, Levy R (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56: 2382–2391PubMedCrossRefGoogle Scholar
  10. Fortin PR, Abrahamowicz M, Ferland D et al.; Canadian Network For Improved Outcomes in Systemic Lupus (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59: 1796–1804PubMedCrossRefGoogle Scholar
  11. Ginzler EM, Wofsy D, Isenberg D et al.; ALMS Grou (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62: 211–221PubMedCrossRefGoogle Scholar
  12. Hiraki LT, Benseler SM, Tyrrell PN et al. (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152: 550–556PubMedCrossRefGoogle Scholar
  13. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725PubMedCrossRefGoogle Scholar
  14. Houssiau FA, Vasconcelos C, D’Cruz D et al. (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61–64PubMedCrossRefGoogle Scholar
  15. Huber Am, Birdi N, McLAine P, Klassen TP, Pothos M (2001) A randomized placebo controlled trial of prednisone in Henoch Schoenlein purpura. Arthritis Rheum 44: S171Google Scholar
  16. Kim S, El-Hallak M, Dedeoglu F (2009) Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 60: 1825–1830PubMedCrossRefGoogle Scholar
  17. Ladd PE, Emery KH, Salisbury SR et al. (2011) Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 197: W153–158PubMedCrossRefGoogle Scholar
  18. Ogata S, Ogihara Y, Honda T (2012) Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129: e17–23PubMedCrossRefGoogle Scholar
  19. Ozen S, Pistorio A, Iusan SM et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69: 798–806PubMedCrossRefGoogle Scholar
  20. Park JM, Won SC, Shin JI, Yim H, Pai KS (2011) Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26: 411–417PubMedCrossRefGoogle Scholar
  21. Pattison NS, Chamley LW, Birdsall M (2000) Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 183: 1008–1012PubMedCrossRefGoogle Scholar
  22. Pons-Estel GJ, Alarcón GS, McGwin G Jr.; Lumina Study Group (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61: 830–839PubMedCentralPubMedCrossRefGoogle Scholar
  23. Tsao BP (2004) Update on human systemic lupuss erythematossuss genetics. Curr Opin Rheumatol 16: 513–521PubMedCrossRefGoogle Scholar
  24. Weiss PF, Klink AJ, Localio R (2010) Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics 126: 674–681PubMedCentralPubMedCrossRefGoogle Scholar
  25. Zulian F, Martini G, Vallongo C (2011) Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63: 1998–2006 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gerd Horneff
    • 2
  • Volker Wahn
    • 1
  1. 1.Campus Virchow, Klinik mit Schwerpunkt Pädiatrische Pneumologie und ImmunologieUniversitätsmedizin Charité BerlinBerlinDeutschland
  2. 2.Zentrum für Allgemeine Pädiatrie und NeonatalogieAsklepios-Klinik Sankt AugustinSankt AugustinDeutschland

Personalised recommendations